A case of acute esophageal variceal hemorrhage.
All those who deal with patients suffering from this discouraging and lethal disease are constantly searching for the ideal method in which to control active hemorrhage from esophageal varices. Continued nonoperative management in those whose hemorrhage does cease on purely conservative measures results in an unacceptably high mortality, the most common cause of which is recurrent bleeding. Those patients who undergo portoazygos disconnection via the transabdominal or transthoracic route are equally prone to recurrent hemorrhage unless an elective portosystemic shunt is performed. Whether such a shunt is done as an elective or as an emergency procedure, the postoperative mortality and morbidity are high. Although protection against recurrent bleeding can be expected in most, the natural history of liver disease progression (and prognosis therefrom) remains unaltered, if not occasionally aggravated. Resurgence of interest in injection sclerotherapy for immediate control of hemorrhage, with subsequent longterm control of varices by repeated injections at intervals of several months, has received enthusiastic support. Preservation of existing hepatocellular function, the simplicity of the technique, especially with the fibreoptic endoscope, and its likely impact on medical care costs in this disease are attractive benefits. It is not perfect, and prospective randomized controlled trials are required to prove its superiority over other forms of treatment, but it currently appears to be the most viable alternative. We are not alone in fervently hoping that portoazygos disconnection will rarely be required and that portosystemic shunting will become a superfluous procedure, comfortably consigned to the history books.
D000208:Acute Disease; D004932:Esophageal and Gastric Varices / Q000601:surgery / Q000628:therapy*; D006471:Gastrointestinal Hemorrhage / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007440:Intubation; D008297:Male; D008722:Methods; D008875:Middle Aged; D012597:Sclerosing Solutions / Q000008:administration & dosage; D014667:Vasopressins / Q000627:therapeutic use
D012597:Sclerosing Solutions; D014667:Vasopressins